CIK 0001799788
- Non-accelerated filer
- Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 205473709
- Phone
- +1 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-10-07 | Patel Snehal CEO and CFO | Purchase | +2,000 | $9.72 | $19K | 2,716,886 |
| 2022-09-30 | Patel Snehal CEO and CFO | Purchase | +1,000 | $9.46 | $9K | 2,714,886 |
| 2022-09-29 | Patel Snehal CEO and CFO | Purchase | +1,000 | $9.23 | $9K | 2,713,886 |
| 2022-06-24 | Patel Snehal CEO and CFO | Purchase | +22,535 | $9.13 | $206K | 2,706,421 |
| 2022-06-24 | Patel Snehal CEO and CFO | Purchase | +6,465 | $9.13 | $59K | 2,712,886 |
| 2022-06-16 | Patel Snehal CEO and CFO | Purchase | +8,000 | $7.13 | $57K | 2,683,886 |
| 2022-06-14 | Patel Snehal CEO and CFO | Purchase | +12,000 | $7.91 | $95K | 2,675,886 |
| 2022-06-10 | Patel Snehal CEO and CFO | Purchase | +12,000 | $8.33 | $100K | 2,663,886 |
| 2022-06-09 | Patel Snehal CEO and CFO | Purchase | +4,500 | $10.90 | $49K | 1,243,453 |
| 2022-06-07 | Patel Snehal CEO and CFO | Purchase | +6,000 | $8.55 | $51K | 1,238,953 |
| 2022-06-03 | Patel Snehal CEO and CFO | Purchase | +9,250 | $8.35 | $77K | 1,232,953 |
| 2022-06-02 | Patel Snehal CEO and CFO | Purchase | +6,774 | $7.38 | $50K | 1,223,703 |
| 2022-04-25 | Daugherty Frank Joseph Chief Medical Officer | Purchase | +1,000 | $16.25 | $16K | 90,121 |
| 2022-04-21 | Patel Snehal CEO and CFO | Purchase | +6,000 | $16.09 | $97K | 1,216,929 |
| 2022-04-19 | Patel Snehal CEO and CFO | Purchase | +6,000 | $16.74 | $100K | 1,210,929 |
| 2022-04-19 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +500 | $16.74 | $8K | 255,995 |
| 2022-02-11 | Patel Snehal CEO and CFO | Purchase | +5,500 | $19.80 | $109K | 1,204,929 |
| 2022-02-04 | Patel Snehal CEO and CFO | Purchase | +5,000 | $19.59 | $98K | 1,199,429 |
| 2022-01-31 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +500 | $18.47 | $9K | 255,495 |
| 2022-01-21 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +500 | $16.33 | $8K | 254,995 |
Page 5 of 7 · 122 trades